The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer research"
DOI: 10.1158/0008-5472.can-18-0440
Abstract: Radiotherapy amplifies p53 expression in cancer cells with wild-type (wt) p53. Blocking the negative regulators MDM2 and MDMX stabilizes p53 and may therefore potentiate radiotherapy outcomes. In this study, we investigate the efficacy of the… read more here.
Keywords: pm2; radiotherapy; type p53; p53 ... See more keywords